7h agoThe FlyBEARISH 28General
Archived explainer. For the current picture see today's NVAX page.
Why Is NOVAVAX INC (NVAX) Stock Down Today?
By the Top Tier Newswire AI Desk · October 16, 2026 at 3:32 PM ET · reviewed against 6 wire stories
NOVAVAX INC (NVAX) is down -13.03% in the latest session. Our newswire has captured 6 stories on NVAX across 4 sources in the last 36 hours, with AI sentiment reading mixed (avg 43/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Novavax Inc (NVAX) shares fell 13.03% to $11.15, marking the steepest decline among major vaccine developers. The selloff reflects broad pressure on the sector, with the smallest name in the group absorbing the heaviest losses.
What Happened
Novavax led the slide among vaccine developers, closing at $11.15 after trading as low as $11.11 in the afternoon. The stock opened at $12.82 and hit a session high of $12.90 at 7:25 AM ET before reversing sharply. Sector peers also faced headwinds, with Moderna tumbling 10% while Pfizer held steady. Citi maintained a Sell rating on the stock but raised its price target to $8 from $7.
What The Data Shows
Trading volume reached 7.3 million shares, which is 1.4 times the three-month daily average. The stock’s beta of 2.43 indicates high volatility relative to the broader market. Fundamentals show the company remains unprofitable with a trailing twelve-month EPS of -1.52. Revenue declined 61.6% over the same period, and the net margin stood at -59.9%. The market cap is currently $2.1 billion. Over the last eight sessions, the stock had moved just 0.3%, rising from $11.22 to $11.25 before today’s drop. The 52-week range spans from $6.20 to $13.38. Recent data shows the stock printed two fresh 52-week highs and 29 fresh 52-week lows on October 16, 2026.
What To Watch
Investors will monitor the breadth of the vaccine sector selloff and whether Novavax can stabilize near its recent lows. The company’s unprofitable status and declining revenue remain key factors in its valuation.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
NVAX by the numbers
Last: $11.15Session: -13.03%7 sessions: +0.27%Coverage: 6 stories / 4 sourcesAI sentiment: 43/100 (mixed)Mkt cap: $2.1B52w: $6.20 to $13.38
The headlines behind the move
8h ago24/7 Wall St.BEARISH 34General
Novavax Plunges 12% as Selloff Hits Vaccine Makers; Moderna Tumbles 10%, Pfizer Holds Steady
Vaccine stocks are under heavy pressure, and the smallest name in the group is taking the heaviest losses. Novavax (NASDAQ:NVAX) stock is down 12% to $11.23 in afternoon trading, leading the slide among vaccine developers. That decline stands out because Novavax relies on a partner to sell its main vaccine. Meanwhile, Moderna (NASDAQ:MRNA) stock is […]
10h agoInvesting.com MarketsBEARISH 38General
Why is Novavax stock sliding today?
Why is Novavax stock sliding today?
10h agoThe FlyBEARISH 34General
Novavax falls -10.4%
1d agoMarketWatchBULLISH 63General
Novavax Inc. stock outperforms competitors on strong trading day
1d agoThe FlyBULLISH 63Analyst
Novavax price target raised to $8 from $7 at Citi
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on NVAX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier NVAX move explainers: 2026-10-16 · 2026-10-09 · 2026-10-07 · 2026-10-06 · 2026-10-05 · 2026-09-10 · 2026-09-02 · 2026-09-01 · 2026-08-28